The new Boston, MA-based biotech, Pyxis Oncology, believes focusing on a better understanding of tumor-reactive T-cells from the core of growing tumors, rather than relying on older approaches originating largely from infectious disease inflammation models, could lead to new families of antibody-based immuno-oncology therapies.
Pyxis Oncology: New Routes To Immuno-Oncology Therapies
Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.
More from Financing
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.